An overview of immunomodulatory intervention in rheumatoid arthritis

Drugs of Today

Volumn 35, Issue 4-5, 1999, Pages 275-286

  Kavanaugh, Arthur ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOMODULATING AGENT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; MONOCLONAL ANTIBODY;

ANIMAL MODEL; CONFERENCE PAPER; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG TOLERABILITY; GENE THERAPY; HUMAN; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOPATHOGENESIS; NONHUMAN; RHEUMATOID ARTHRITIS; T LYMPHOCYTE ACTIVATION;

EID: 0032807821     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.1999.35.4-5.552203     Document Type: Conference Paper

References (76)

1. Kushner, I. Does aggressive therapy of rheumatoid arthritis affect outcome? J Rheumatol 1989, 16: 1-4.
2. Wolfe, F. Fifty years of antirheumatic therapy: The prognosis of rheumatoid arthritis. J Rheumatol 1990, 17 (Suppl.): 24-32.
3. Situnayake, R., Gringulis, K., McConkey, B. Long-term treatment of RA with sulphasalazine, gold, or penicillamine: A comparison using life-table methods. Ann Rheum Dis 1987, 46: 177-83.
4. Harris, E.D. Rheumatoid arthritis: Pathophysiology and implications for therapy. New Engl J Med 1990, 322: 1277-89.
5. Kingsley, G., Pitzalis, C., Panayi, G.S. Immunogenetic and cellular immune mechanisms in rheumatoid arthritis: Relevance to new therapeutic strategies. Br J Rheumatol 1990, 29: 58-64.
6. Kavanaugh, A., Lipsky, P. The application of biotechnological advances to the treatment of RA. In: Rheumatoid Arthritis: Pathogenesis, Assessment, Outcome and Treatment. F. Wolfe and T. Pincus (Eds.). Marcel Dekker: New York 1994, 373-99.
7. Cush, J.J., Kavanaugh, A.F. Biologic interventions in rheumatoid arthritis. Rheum Dis Clin N Amer 1995, 23: 797-816.
8. Fox, D.A. Biological therapies: A novel approach to the treatment of autoimmune disease. Am J Med 1995, 99: 82-8.
9. Goronzy, J., Weyand, C. T- and B-cell-dependent pathways in rheumatoid arthritis. Curr Opin Rheum 1995, 7: 214-21.
10. Panayi, G., Lanchbury, J., Kingsley, G. The importance of the T-cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis. Arthritis Rheum 1992, 35: 729-35.
11. Dolhain, R., van der Heiden, A., ter Haar, N., Breedveld, F., Miltenburg, A. Shift toward T-lymphocytes with a T-helper 1 cytokine-secretion profile in the joints of patients with rheumatoid arthritis. Arthritis Rheum 1996, 29: 1961-9.
12. Miossec, P., van den Berg, W. Th1/Th2 cytokine balance in arthritis. Arthritis Rheum 1997, 40: 2105-15.
13. Maurice, M., Nakamura, H., van der Voort, E. et al. Evidence for the role of an altered redox state in hyporesponsiveness of synovial T-cells in rheumatoid arthritis. J Immunol 1997, 158: 1458-65.
14. Salmon, M., Scheel-Toellner, D., Huisson, A., et al. Inhibition of T-cell apoptosis in the rheumatoid synovium. J Clin Invest 1997, 99: 439-46.
15. Firestein, G., Zvaifler, N. How important are T-cells in chronic rheumatoid synovitis? Arthritis Rheum 1990, 33: 768-73.
16. Zvaifler, N., Firestein, G. Pannus and pannocytes, alternative models of joint destruction in rheumatoid arthritis. Arthritis Rheum 1994, 37: 783-9.
17. Burmester, G., Stuhlmüller, B., Keyszer, G., Kinne, R. Mononuclear phagocytes and rheumatoid synovitis, mastermind or workhorse in arthritis. Arthritis Rheum 1997, 40: 5-18.
18. Springer, T. Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm. Cell 1994, 76: 301-14.
19. Kavanaugh, A. Antiadhesion therapy in rheumatoid arthritis: A review of recent progress. BioDrugs, Clin Immunother 1997, 7: 119-33.
20. Campion, G. The prospect for cytokine-based therapeutic strategies in rheumatoid arthritis. Ann Rheum Dis 1994, 53: 485-7.
21. Opdenakker, G., van Damme, J. Cytokine-regulated proteases in autoimmune disease. Immunol Today 1994, 15: 103-6.
22. Cope, A., Liblau, R., Yang, X.-D. et al. Chronic tumor necrosis factor alters T-cell responses by attenuating T-cell receptor signaling. J Exp Med 1997, 185: 1573-84.
23. Pennisi, E. Teetering on the brink of danger. Science 1996, 271: 1665-7.
24. Beverley, P. Is T-cell memory maintained by crossreactive stimulation? Immunol Today 1990, 11: 203-5.
25. Cyster, J., Hartley, S., Goodnow, C. Competition for follicular niches excludes self-reactive cells from the recirculating B-cell repertoire. Nature 1994, 371: 389-95.
26. Uno, K., Suguro, T., Nohira, K. et al. Comparison of indium-111-labeled leukocyte scintigraphy and technetium-99m joint scintigraphy in rheumatoid arthritis and osteoarthritis. Ann Nucl Med 1992, 6: 247-51.
27. Elliott, M., Maini, R. New directions for biological therapy in rheumatoid arthritis. Int Arch Allergy Immunol 1994, 104: 112-25.
28. Miller, S., Karpus, W. The immunopathogenesis and regulation of T-cell-mediated demyelinating disease. Immunol Today 1994, 15: 356-61.
29. Alam, A., Lambert, N., Lule, J. et al. Persistence of dominant T-cell clones in synovial tissues during rheumatoid arthritis. J Immunol 1996, 156: 3480-5.
30. Kato, T., Kurokawa, M., Masuko-Hongo, K. et al. T-cell clonality in synovial fluid of a patient with rheumatoid arthritis. J Immunol 1997, 159: 5143-9.
31. Moreland, L., Heck, L., Koopman, W. et al. Vβ17 T-cell receptor peptide vaccination in rheumatoid arthritis: Results of a phase I dose escalation study. J Rheum 1996, 23: 1353-62.
32. Smith, J., Fort, J. Treatment of rheumatoid arthritis by immunization with mononuclear white blood cells: Results of a preliminary trial. J Rheumatol 1996, 23: 220-5.
33. Kingsley, G. Class II MHC binding peptides: A feasible treatment for arthritis? Clin Exp Rheumatol 1992, 10: 297-300.
34. Vladutiu, A. Treatment of autoimmune diseases with antibodies to class II major histocompatibility complex antigens. Clin Immunol Immunop 1991, 61: 1-17.
35. Zanelli, E., Gonzalez-Gay, M., David, C. Could HLA-DRβ1*0401 be the protective locus in rheumatoid arthritis? Immunol Today 1995, 16: 274-8.
36. Weiner, H. Oral tolerance: Immune mechanisms and treatment of autoimmune diseases. Immunol Today 1997, 18, 335-42.
37. Sieper, J., Kary, S., Sörenson, H. et al. Oral type II collagen treatment in early rheumatoid arthritis. Arthritis Rheum 1996, 39: 41-51.
38. + T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997, 389: 737-42.
39. Reiser, H., Stadecke, M. Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases. New Engl J Med 1996, 335: 1369-77.
40. Greenwald, R., Lu, P., Halvorson, M. et al. Effects of blocking B7-1 and B7-2 interactions during a type 2 in vivo immune response. J Immunol 1997, 158: 4088-96.
41. Daikh, D., Finck, B., Linsley, P., Hollenbough, D., Wofsy, D. Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways. Immunol Today 1997, 159: 3104-8.
42. Datta, S., Kalled, S. CD40-CD40 ligand interaction in autoimmune disease. Arthritis Rheum 1997, 40: 1735-45.
43. Horneff, G., Burmester, G.R., Emmrich, F., Kalden, J. Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody. Arthritis Rheum 1991, 34: 129-40.
44. Moreland, L.W., Bucy, R.P., Tilden, A. et al. Use of a chimeric monoclonal anti-CD4 antibody in patients with refractory rheumatoid arthritis. Arthritis Rheum 1993, 36: 307-15.
45. Van der Lubbe, P.A., Dijkmans, B.A.C., Markusse, H.M., Nässander, U., Breedveld, F.C. A randomized, double-blind, placebo-controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis. Arthritis Rheum 1995, 38: 1097-106.
46. Rep, M., van Oosten, B., Roos, M., Ader, H., Polman, C., van Lier, R. Treatment with depleting CD4 monoclonal antibody results in a preferential loss of circulating naive T-cells but does not affect IFN-γ secreting Th1 cells in human. J Clin Invest 1997, 99: 2225-31.
47. Siveke, J., Hamann, A. Cutting edge: T-helper 1 and T-helper 2 cells respond differently to chemokines. J Immunol 1998, 160: 550-4.
48. Carson, D., Raz, E. Oligonucleotide adjuvants for T-helper 1 (Th1)-specific vaccination. J Exp Med 1997, 186: 1621-2.
49. Ross, S., Williams, R., Mason, L. et al. Suppression of TNF-α expression, inhibition of Th1 activity, and amelioration of collagen-induced arthritis by rolipram. J Immunol 1997, 159: 6253-9.
50. Kincy-Cain, T., Bost, K. Substance P-induced IL-12 production by murine macrophages. J Immunol 1997, 158: 2334-9.
51. Wicks, I., Cooley, H., Szer, J. Autologous hemopoietic stem cell transplantation: A possible cure for rheumatoid arthritis? Arthritis Rheum 1997, 40: 1005-11.
52. Arend, W.P., Dayer, J.M. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis. Arthritis Rheum 1995, 38: 151-60.
53. Firestein, G., Zvaifler, N. Anticytokine therapy in rheumatoid arthritis. New Engl J Med 1997, 337: 195-7.
54. Brenner, T., Brocke, S., Szafer, F. et al. Inhibition of nitric oxide synthase for treatment of experimental autoimmune encephalomyelitis. J Immunol 1997, 158: 2940-6.
55. Herrero-Beaumont, G., Egido, J. PAF, a potent proinflammatory mediator, looking for its role in the pathogenesis of joint damage. Ann Rheum Dis 1997, 56: 211-3.
56. Winter, G., Harris, W. Humanized antibodies. Immunol Today 1993, 14: 243-6.
57. Katre, N. Immunogenicity of recombinant IL-2 modified by covalent attachment of polyethylene glycol. J Immunol 1990, 144: 209-13.
58. Ghetie, V., Popov, S., Borvak, J. et al. Increasing the serum persistence of an IgG fragment by random mutagenesis. Nat Biotechnol 1997, 15: 637-40.
59. Marks, C., Marks, J. Phage libraries - A new route to clinically useful antibodies. New Engl J Med 1996, 335, 730-3.
60. Lonberg, N., Taylor, L., Harding, F. et al. Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature 1994, 368: 856-9.
61. Houdebine, L.-M. Production of pharmaceutical proteins from transgenic animals. J Biotechnol 1994, 34: 269-87.
62. Kerr, D., Liang, F., Bondioli, K. et al. The bladder as a bioreactor: Urothelium production and secretion of growth hormone into urine. Nat Biotechnol 1998, 16: 75-9.
63. Moreland, L., Baumgartner, S., Schiff, M. et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. New Engl J Med 1997, 337: 141-7.
64. Okun, I., Veerapandian, P. New methods to mimic nature in high-throughput screening. Nat Biotechnol 1997, 15: 287-8.
65. Coller, B. Platelet gpIIb/IIIa antagonists: The first anti-integrin receptor therapeutics. J Clin Invest 1997, 99: 1467-71.
66. Takasaki, W., Kajino, Y., Kajino, K., Murali, R., Greene, M. Structure-based design and characterization of exocyclic peptidomimetics that inhibit TNF-α binding to its receptor. Nat Biotechnol 1007, 15: 1266-70.
67. Ansari, F., McDonnell, W. Molecular medicine: Antisense-oligonucleotide therapy. New Engl J Med 1996, 334: 316-8.
68. Bennett, C., Condon, T., Grimm, S., Chan, H., Chiang, M. Inhibition of endothelial cell adhesion molecule expression with antisense oligonucleotides. J Immunol 1994, 152: 3530-40.
69. Wrighton, C., Hofer-Warbinek, R., Moll, T., Eytner, R., Bach, F., de Martin, R. Inhibition of endothelial cell activation by adenovirus-mediated expression of IκBα, an inhibitor of the transcription factor NF-κB. J Exp Med 1996, 183: 1013-22.
70. Spragg, D., Alford, D., Greferath, R. et al. Immunotargeting of liposomes to activated vascular endothelial cells: A strategy for site-selective delivery in the cardiovascular system. Proc Natl Acad Sci USA, 1997, 94: 8795-800.
71. van de Winkel, J., Bast, B., de Gast, G. Immunotherapeutic potential of bispecific antibodies. Immunol Today 1997, 18: 562-4.
72. Larkin, M. Out with the jab, in with painless pills. Lancet 1997, 349: 1676.
73. Eliot, M., Maini, R., Feldmann, M. et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha versus placebo in rheumatoid arthritis. Lancet 1994, 344: 1105-9.
74. Kavanaugh, A. Anti-tumor necrosis factor-α monoclonal antibody therapy for rheumatoid arthritis. Rheum Dis Clin North Am 1998, 24: 593-614.
75. Kavanaugh, A., Davis, L., Nichols, L., et al. Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule-1. Arthritis Rheum 1994, 37: 992-9.
76. Kavanaugh, A., Heudebert, G., Cush, J., Jain, R. Cost evaluation of novel therapies in rheumatoid arthritis. Semin Arthritis Rheum 1996, 25: 297-307.